Meeting
2012 ASCO Annual Meeting
Topoisomerase II alpha gene status, HER2, and microtubule-associated protein tau as predictors of pathologic complete response after neoadjuvant chemotherapy.
Authors
Agust Barnadas
Hospital de la Santa Creu i Sant Pau, Medical Oncology Department, Barcelona, Spain
Agust Barnadas , Ariadna Tibau Martorell , Laura Lopez Vilaro , Daniel Escuin , M Carmen Alonso , Belen Ojeda , Teresa Ramon y Cajal , M Josefa Fuentes , Jose Ignacio Perez Garcia , Barbara Garcia Valdecasas , Montserrat Clotet , M Sofia Torrubia , Ignasi Gich , Enrique Lerma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Genomic and Epigenomic Biomarkers
Citation
J Clin Oncol 30, 2012 (suppl; abstr 10555)
DOI
10.1200/jco.2012.30.15_suppl.10555
Abstract #
10555
Poster Bd #
44D
Abstract Disclosures
Similar Posters
First Author: Jose Pacheco
Poster
2023 ASCO Annual Meeting
Artificial intelligence (AI) –based machine learning models (ML) for predicting pathological complete response (pCR) in patients with hormone receptor (HoR) –positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT): A retrospective cohort study.
First Author: Luca Mastrantoni
Poster
2020 ASCO Virtual Scientific Program
Predictor of trastuzumab-induced cardiotoxicity in breast cancer (BC) patients: HER2/neu 655 polymorphisms, biochemical and clinical features.
First Author: Isabel Blancas
Poster
2018 ASCO Annual Meeting
Does the sequence of anthracycline and taxane matter? The NeoSAMBA trial.
First Author: Jose Bines